Ana Belo van Wijk, PhD,  —

Polyphor Gets New Funding to Develop Inhaled Antibiotic Murepavadin for Respiratory Diseases Like CF

Polyphor and the European Innovative Medicines Initiative (IMI) will fund up to 10 million euros (around $11.6 million U.S.) to support and advance the development of an inhaled formulation of Polyphor’s investigational antibiotic murepavadin (POL7080). Polyphor is investing 5 million euros into the development project; the IMI will provide up…

HOPE-1 Clinical Trial for SPX-101 Is Enrolling CF Patients in Canada and Europe

The first patient has been enrolled and dosed in the HOPE-1 Phase 2 clinical trial evaluating Spyryx Biosciences‘ investigational drug SPX-101 as a treatment for cystic fibrosis (CF). The HOPE-1 study (NCT03229252) will take place in Alberta and Ontario in Canada, the United Kingdom, France, and Portugal. Clinical…

Enrollment Underway in CF Clinical Trial for Ear Toxicity Caused by Antibiotics

The first study of cystic fibrosis (CF) patients who received antibiotics that caused inner ear disease or ototoxicity is enrolling participants, according to Sound Pharmaceuticals. The Phase 1b STOP Ototoxicity study (NCT02819856) is led by Dr. Patrick Flume, MD,…

Antibiotic Iclaprim Granted FDA Orphan Drug Status for CF Lung Infections

The U.S. Food and Drug Administration (FDA) granted orphan drug status to a broad spectrum antibiotic called iclaprim, developed by Motif Bio, for the treatment of one of the most common lung infections in patients with cystic fibrosis (CF), Staphylococcus aureus. The FDA’s designation could accelerate the availability of iclaprim for CF patients.